Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

In AD, a small peptide, amyloid β-protein (Aβ), forms long, insoluble amyloid fibrils, which accumulate in spherical microscopic deposits known as senile plaques. However, the relevance of these ...

Figure 1: Imaging of amyloid-β deposits in the live mouse. Figure 3: In vivo imaging of amyloid-β deposits in 20-month-old homozygous PDAPP mice. Immunostaining with biotinylated or ...

The beta amyloid peptide (Abeta) is the primary component of the senile plaques observed in the brains of Alzheimer's patients, and this peptide is toxic to neurons and other cells in many different ...

CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...

One such assembly, amyloid beta peptide, is synonymous with dementia, but researchers were not certain how these peptide ...

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...

The study, titled "Effects of amyloid-β-mimicking peptide hydrogel matrix on neuronal ... designed to mimic the amyloid-beta (β) containing microenvironment associated with AD.